Arrowhead Pharmaceuticals Completes Enrollment In Global Phase 3 Yosemite Study Of Zodasiran For The Treatment Of Homozygous Familial Hypercholesterolemia
ARWR•Phase 3 Yosemite enrollment completed
- Arrowhead Pharmaceuticals said it has completed enrollment in the global Phase 3 Yosemite study of zodasiran for the treatment of homozygous familial hypercholesterolemia.
- The company said completion of the Yosemite Phase 3 study is anticipated in mid-2027.
